What is the cure rate of Fruquintinib?

Fruquintinib (Fruquintinib) is a targeted therapy drug mainly used for the treatment of digestive system tumors such as advanced colorectal cancer and gastric cancer. However, it needs to be emphasized that there is currently no drug that is 100% guaranteed to cure cancer. The main goals of cancer treatment are to delay the progression of the disease, relieve symptoms, and improve survival rates. For advanced cancer, the focus of treatment is usually to prolong the patient's survival time and improve the quality of life.

Fruquintinib blocks angiogenesis and slows tumor growth by inhibiting vascular endothelial growth factor receptor (VEGFR). Clinical trials and studies have shown that fruquintinib can achieve a certain anti-tumor effect in some patients, prolong the time of disease progression, and improve the survival rate of patients. However, the specific cure rate is difficult to clearly determine because the effectiveness of cancer treatment is affected by many factors, including the patient's overall health status, the biological characteristics of the tumor, and the choice of treatment options.

During the period of treatment with fruquintinib, patients should closely cooperate with their doctors’ recommendations and undergo regular follow-up and examinations. The doctor will adjust the treatment plan according to the patient's condition to ensure the best treatment effect. In some cases, doctors may combine fruquintinib with other treatments to increase the overall effectiveness of treatment.

Overall, for advanced cancers, including colorectal and gastric cancers, the cure rate is relatively low, and the goals of treatment focus more on delaying disease progression and improving survival rates. The application of fruquintinib in this area provides an optional treatment option for some patients, but patients and doctors need to consider multiple factors when making treatment decisions and develop individualized treatment plans.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.